View Post

The Next-Generation Promise of ADCs and SERDs in Breast Cancer

In In The News by Barbara Jacoby

By: Lisa Astor From: targetedonc.com The generation in development offers reasons for excitement about improved outcomes for patients with breast cancer. In 2022, development of novel targeted therapies has focused on antibody-drug conjugates (ADCs) and selective estrogen receptor degraders (SERDs). Both classes of agents have shown mixed efficacy over time. The generation in development offers reasons for excitement about improved …